Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor

Cancer Res. 1994 Feb 15;54(4):903-7.

Abstract

We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50% inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to > 10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rh1, which was resistant to RAP in serum-containing medium (50% inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on complexing with the cytosolic FK506-binding protein for activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carrier Proteins / physiology
  • Cell Division / drug effects
  • Child
  • Colonic Neoplasms / pathology*
  • Heat-Shock Proteins / physiology
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Polyenes / pharmacology*
  • Receptor, IGF Type 1 / physiology*
  • Rhabdomyosarcoma / pathology*
  • Sirolimus
  • Tacrolimus / pharmacology
  • Tacrolimus Binding Proteins
  • Tumor Cells, Cultured

Substances

  • Carrier Proteins
  • Heat-Shock Proteins
  • Immunosuppressive Agents
  • Polyenes
  • Receptor, IGF Type 1
  • Tacrolimus Binding Proteins
  • Sirolimus
  • Tacrolimus